This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, eHealth) (353)

Published on in Vol 9, No 7 (2020): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16319, first published .
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study

Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study

Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study

Authors of this article:

Jane S Hankins1 Author Orcid Image ;   Nirmish Shah2 Author Orcid Image ;   Lisa DiMartino3 Author Orcid Image ;   Donald Brambilla3 Author Orcid Image ;   Maria E Fernandez4 Author Orcid Image ;   Robert W Gibson5 Author Orcid Image ;   Victor R Gordeuk6 Author Orcid Image ;   Richard Lottenberg7 Author Orcid Image ;   Abdullah Kutlar5 Author Orcid Image ;   Cathy Melvin8 Author Orcid Image ;   Jena Simon9 Author Orcid Image ;   Ted Wun10 Author Orcid Image ;   Marsha Treadwell11 Author Orcid Image ;   Cecelia Calhoun12 Author Orcid Image ;   Ana Baumann12 Author Orcid Image ;   Michael B Potter13 Author Orcid Image ;   Lisa Klesges12 Author Orcid Image ;   Hayden Bosworth2 Author Orcid Image ;   Sickle Cell Disease Implementation Consortium14
Article Authors Cited by (19) Tweetations (2) Metrics

Journals

  1. Hodges J, Phillips S, Norell S, Nwosu C, Khan H, Luo L, Badawy S, King A, Tanabe P, Treadwell M, Rojas Smith L, Calhoun C, Hankins J, Porter J. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Advances 2020;4(18):4463 View
  2. Gimpel H, Manner-Romberg T, Schmied F, Winkler T. Understanding the evaluation of mHealth app features based on a cross-country Kano analysis. Electronic Markets 2021;31(4):765 View
  3. Ibemere S, Tanabe P, Bonnabeau E, Rains G, Eason K, Earls M, Shah N. Awareness and Use of the Sickle Cell Disease Toolbox by Primary Care Providers in North Carolina. Journal of Primary Care & Community Health 2021;12 View
  4. Dawson A, Mullen K, Janson I, Henriksen B, Duncan N, O’Brien D, Meier E. A Feasibility Pilot Study of Online Modules of Hydroxyurea and Sickle Cell Disease Care for Adolescents and Young Adults for Family Medicine Residents. Journal of Pediatric Hematology/Oncology 2022;44(2):e313 View
  5. Smeltzer M, Howell K, Treadwell M, Preiss L, King A, Glassberg J, Tanabe P, Badawy S, DiMartino L, Gibson R, Kanter J, Klesges L, Hankins J. Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. BMJ Open 2021;11(11):e050880 View
  6. Hankins J, Potter M, Fernandez M, Melvin C, DiMartino L, Jacobs S, Bosworth H, King A, Simon J, Glassberg J, Kutlar A, Gordeuk V, Shah N, Baumann A, Klesges L. Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease. Frontiers in Health Services 2023;2 View
  7. Longoria J, Pugh N, Gordeuk V, Hsu L, Treadwell M, King A, Gibson R, Kayle M, Crego N, Glassberg J, Melvin C, Hankins J, Porter J. Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. American Journal of Hematology 2021;96(11):1396 View
  8. Badawy S, DiMartino L, Brambilla D, Klesges L, Baumann A, Burns E, DeMartino T, Jacobs S, Khan H, Nwosu C, Shah N, Hankins J. Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study. JMIR Formative Research 2022;6(10):e41415 View
  9. Manwani D, Burnett A, Paulose J, Yen G, Burton T, Anderson A, Wang S, Lee S, Saraf S. Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis. eJHaem 2022;3(4):1135 View
  10. Hankins J, Klesges L. Bridging the implementation gap in medication adherence. If you build it, will they come?. British Journal of Haematology 2022;196(1):17 View
  11. Rai P, Okhomina V, Kang G, Martinez H, Hankins J, Joshi V. Longitudinal effect of disease‐modifying therapy on left ventricular diastolic function in children with sickle cell anemia. American Journal of Hematology 2023;98(6):838 View
  12. Kandonga D, Sangeda R, Masamu U, Kazumali E, Jonathan A, Msangawale M, Kaihula W, Rwegalulila J, Ondego J, Tutuba H, Ndunguru J, Ambrose E, Kidenya B, Yonazi M, Kyomugisha I, Mupfururirwa W, Jonas M, Nembaware V, Mazandu G, Kengne A, Wonkam A, Makani J, Balandya E. Development of the sickle Pan-African research consortium registry in Tanzania: opportunity to harness data science for sickle cell disease. Frontiers in Hematology 2023;2 View
  13. Devarashetty S, Grewal U, Le Blanc K, Walton J, Jones T, Shi R, Master S, Mansour R, Ramadas P. Sickle cell disease and coronavirus disease-2019 (COVID-19) infection: a single-center experience. Postgraduate Medical Journal 2023;99(1175):1008 View
  14. Elsabagh A, Elhadary M, Elsayed B, Elshoeibi A, Ferih K, Kaddoura R, Alkindi S, Alshurafa A, Alrasheed M, Alzayed A, Al-Abdulmalek A, Altooq J, Yassin M. Artificial intelligence in sickle disease. Blood Reviews 2023;61:101102 View
  15. Piel F, Rees D, DeBaun M, Nnodu O, Ranque B, Thompson A, Ware R, Abboud M, Abraham A, Ambrose E, Andemariam B, Colah R, Colombatti R, Conran N, Costa F, Cronin R, de Montalembert M, Elion J, Esrick E, Greenway A, Idris I, Issom D, Jain D, Jordan L, Kaplan Z, King A, Lloyd-Puryear M, Oppong S, Sharma A, Sung L, Tshilolo L, Wilkie D, Ohene-Frempong K. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology 2023;10(8):e633 View
  16. Hankins J, Brambilla D, Potter M, Kutlar A, Gibson R, King A, Baumann A, Melvin C, Gordeuk V, Hsu L, Nwosu C, Porter J, Alberts N, Badawy S, Simon J, Glassberg J, Lottenberg R, DiMartino L, Jacobs S, Fernandez M, Bosworth H, Klesges L, Shah N. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Blood Advances 2023;7(23):7190 View
  17. Nwosu C, Khan H, Masese R, Nocek J, Gollan S, Varughese T, Bourne S, Clesca C, Jacobs S, Baumann A, Klesges L, Shah N, Hankins J, Smeltzer M. Recruitment Strategies in the Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization Study (meSH): Multicenter Survey Study. JMIR Formative Research 2024;8:e48767 View
  18. Mendez G, Nocek J, Brambilla D, Jacobs S, Cole O, Kanter J, Glassberg J, Saving K, Melvin C, Gibson R, Treadwell M, Jackson G, King A, Gordeuk V, Kroner B, Hsu L. Social determinants of health and treatment center affiliation: analysis from the sickle cell disease implementation consortium registry. BMC Health Services Research 2024;24(1) View
  19. Knight L, Tanabe P, Blewer A, Goodrich J, King A, Reuter‐Rice K, Crego N. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease. Pediatric Blood & Cancer 2024;71(7) View